Skip to main content

Advertisement

Table 3 Clinical characteristics of NPC patients in the training, retrospective validation, and prospective validation cohorts

From: A new prognostic histopathologic classification of nasopharyngeal carcinoma

Characteristic Training cohort Retrospective validation cohort Prospective validation cohort
Total (cases) 2716 1702 1613
Age (years)
 Median (range) 46 (10–86) 47 (10–90) 47 (11–83)
Follow-up time (months)
 Median (range) 68 (1–120) 68 (1–120) 41 (1–91)
Sex [cases (%)]
 Female 658 (24.2) 501 (29.4) 404 (25.1)
 Male 2058 (75.8) 1201 (70.6) 1209 (74.9)
Clinical stage [cases (%)]
 I 75 (2.8) 67 (4.0) 35 (2.2)
 II 549 (20.2) 388 (22.8) 104 (6.5)
 III 1272 (46.8) 695 (40.8) 458 (28.4)
 IV 820 (30.2) 552 (32.4) 1016 (62.9)
Therapeutic modality [cases (%)]
 Radiotherapy alone 1592 (58.6) 928 (54.5) 220 (13.6)
 Radiochemotherapy 1124 (41.4) 774 (45.5) 1393 (86.4)
Proposed classification [cases (%)]
 EC 1520 (55.9) 987 (58.0) 1202 (74.5)
 MSEC 598 (22.0) 420 (24.7) 229 (14.2)
 SC 489 (18.0) 198 (11.6) 135 (8.4)
 SCC 109 (4.1) 97 (5.7) 47 (2.9)
WHO classification [case (%)]
 NKUC 2261 (83.2) 1425 (83.8) 1185 (73.5)
 NKDC 409 (15.1) 227 (13.3) 414 (25.7)
 KSCC 46 (1.7) 50 (2.9) 14 (0.8)
OS rate (%)
 5-year (95% CI) 68.7 (66.9–70.5) 73.3 (71.1–75.4) 83.5 (81.1–85.6)
  1. NPC nasopharyngeal carcinoma, EC epithelial carcinoma, SC sarcomatoid carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SCC squamous cell carcinoma, WHO World Health Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC non-keratinizing differentiated carcinoma, KSCC keratinizing squamous cell carcinoma, OS overall survival, CI confidence interval